A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia
Latest Information Update: 17 Nov 2026
At a glance
- Drugs Ofirnoflast (Primary) ; Darbepoetin-alfa; Epoetin alfa
- Indications Myelodysplastic syndromes
- Focus Proof of concept; Therapeutic Use
- Sponsors Halia Therapeutics
Most Recent Events
- 10 Nov 2026 Status changed from active, no longer recruiting to completed.
- 17 Sep 2026 Planned End Date changed from 14 Aug 2026 to 15 Oct 2026.
- 04 Aug 2026 Planned End Date changed from 25 May 2026 to 14 Aug 2026.